Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc.GLUE · Entity 4828 | Chief Business Officer | January 02, 2024 | January 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Monte Rosa Therapeutics, Inc.
Report date January 02, 2024 · Filed January 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.71 · Expires 2034-01-01 | Direct | 79,000 |
Reported balance
After 2024-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-02 · Grant · Acquired 79,000 · Balance 79,000 F1: 25% of this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2024 Filed Jan 4, 2024 16:15 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 79,000 | $0.00 Strike: $5.71 | $0.00 |
DisclosureSEC source: 0001209191-24-000766 · doc4.xml · derivative · entry 1 Jones Jullian G · CIK 0001895356 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,000 Underlying: Common Stock · 79,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 16:30 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 77,450 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-23-000949 · doc4.xml · derivative · entry 1 Jones Jullian G · CIK 0001895356 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,450 Underlying: Common Stock · 77,450 shares Expires 2033-01-02 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 18:49 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 73,300 | $0.00 Strike: $13.41 | $0.00 |
DisclosureSEC source: 0000899243-22-008711 · doc4.xml · derivative · entry 1 Jones Jullian G · CIK 0001895356 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,300 Underlying: Common Stock · 73,300 shares Expires 2032-02-29 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.